Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Trial Profile

Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine (Primary) ; Doxazosin (Primary) ; Lisinopril (Primary) ; ACE inhibitors; Antihypertensives; Atenolol; Chlortalidone; Diuretics; Pravastatin
  • Indications Cardiovascular disorders; Heart failure; Hyperlipidaemia; Hypertension; Stroke
  • Focus Therapeutic Use
  • Acronyms ALLHAT
  • Most Recent Events

    • 03 Aug 2022 Results of secondary analysis comparing the use of chlorthalidone, amlodipine, or lisinopril on the primary outcome of combined coronary heart disease, stroke, or all-cause mortality in patients with isolated systolic hypertension or isolated diastolic hypertension, published in the American Heart Journal.
    • 01 Aug 2021 Results (n=5234) assessing determine the association between the percentage of visits with sustained BP control and incident high-cost multimorbidity cluster dyads and triads published in the Journal of General Internal Medicine
    • 09 May 2020 Results presented at the 2020 Annual Scientific Meeting of the American Geriatrics Society
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top